Logo image of ICU

SEASTAR MEDICAL HOLDING CORP (ICU) Stock Price, Forecast & Analysis

USA - Nasdaq - NASDAQ:ICU - US81256L2034 - Common Stock

2.27 USD
-0.01 (-0.44%)
Last: 1/21/2026, 8:00:03 PM
2.2901 USD
+0.02 (+0.89%)
After Hours: 1/21/2026, 8:00:03 PM

ICU Key Statistics, Chart & Performance

Key Statistics
Market Cap81.83M
Revenue(TTM)881.00K
Net Income(TTM)-13.66M
Shares36.05M
Float35.78M
52 Week High30.7
52 Week Low2.2
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)-8.4
PEN/A
Fwd PEN/A
Earnings (Next)03-25
IPO2021-01-26
Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Equipment
ICU short term performance overview.The bars show the price performance of ICU in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -20 -40 -60

ICU long term performance overview.The bars show the price performance of ICU in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of ICU is 2.27 USD. In the past month the price decreased by -7.27%. In the past year, price decreased by -85.54%.

SEASTAR MEDICAL HOLDING CORP / ICU Daily stock chart

ICU Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

ICU Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to ICU. The financial health of ICU is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ICU Financial Highlights

Over the last trailing twelve months ICU reported a non-GAAP Earnings per Share(EPS) of -8.4. The EPS increased by 32.15% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -87.99%
ROE -119.2%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-18.18%
Sales Q2Q%169.12%
EPS 1Y (TTM)32.15%
Revenue 1Y (TTM)1195.59%

ICU Forecast & Estimates

5 analysts have analysed ICU and the average price target is 10.2 USD. This implies a price increase of 349.34% is expected in the next year compared to the current price of 2.27.

For the next year, analysts expect an EPS growth of 91.82% and a revenue growth 385.51% for ICU


Analysts
Analysts80
Price Target10.2 (349.34%)
EPS Next Y91.82%
Revenue Next Year385.51%

ICU Ownership

Ownership
Inst Owners3.03%
Ins Owners0.75%
Short Float %N/A
Short Ratio0.56

ICU Latest News, Press Relases and Analysis

ICU Competitors/Peers

The largest stocks on the US markets in the "Health Care Equipment" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABT ABBOTT LABORATORIES 24.19 209.93B
ISRG INTUITIVE SURGICAL INC 60.82 185.65B
SYK STRYKER CORP 27.56 138.80B
BSX BOSTON SCIENTIFIC CORP 31.09 135.95B
BDX BECTON DICKINSON AND CO 14.3 58.85B
IDXX IDEXX LABORATORIES INC 55.23 55.61B
EW EDWARDS LIFESCIENCES CORP 33.13 49.41B
RMD RESMED INC 26.19 37.85B
GEHC GE HEALTHCARE TECHNOLOGY 17.67 36.94B
DXCM DEXCOM INC 38.77 28.12B
PODD INSULET CORP 62.35 20.05B
ZBH ZIMMER BIOMET HOLDINGS INC 10.7 17.15B

Related stock screener links

About ICU

Company Profile

ICU logo image Seastar Medical Holding Corp. operates as a holding company whose subsidiaries manufacture and supply medical devices. The company is headquartered in Denver, Colorado and currently employs 19 full-time employees. The company went IPO on 2021-01-26. The Company’s Selective Cytopheretic Device (SCD) is designed as a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation and creates a cascade of events that wreak havoc in the patient’s body. The company has broad potential applications for patients suffering from both acute and chronic kidney disease as well as cardiovascular and other serious inflammatory diseases. Its SCD therapy is an extracorporeal synthetic membrane device designed to bind activated leukocytes (neutrophils and monocytes) when integrated into an existing continuous renal replacement therapy (CRRT) circuit in conjunction with the use of regional citrate anticoagulation (RCA).

Company Info

SEASTAR MEDICAL HOLDING CORP

3513 Brighton Blvd, Suite 410

Denver COLORADO US

Employees: 19

ICU Company Website

ICU Investor Relations

Phone: 18444278100

SEASTAR MEDICAL HOLDING CORP / ICU FAQ

Can you describe the business of SEASTAR MEDICAL HOLDING CORP?

Seastar Medical Holding Corp. operates as a holding company whose subsidiaries manufacture and supply medical devices. The company is headquartered in Denver, Colorado and currently employs 19 full-time employees. The company went IPO on 2021-01-26. The Company’s Selective Cytopheretic Device (SCD) is designed as a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation and creates a cascade of events that wreak havoc in the patient’s body. The company has broad potential applications for patients suffering from both acute and chronic kidney disease as well as cardiovascular and other serious inflammatory diseases. Its SCD therapy is an extracorporeal synthetic membrane device designed to bind activated leukocytes (neutrophils and monocytes) when integrated into an existing continuous renal replacement therapy (CRRT) circuit in conjunction with the use of regional citrate anticoagulation (RCA).


What is the current price of ICU stock?

The current stock price of ICU is 2.27 USD. The price decreased by -0.44% in the last trading session.


Does ICU stock pay dividends?

ICU does not pay a dividend.


What is the ChartMill technical and fundamental rating of ICU stock?

ICU has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


Which stock exchange lists ICU stock?

ICU stock is listed on the Nasdaq exchange.


What is the Price/Earnings (PE) ratio of SEASTAR MEDICAL HOLDING CORP (ICU)?

SEASTAR MEDICAL HOLDING CORP (ICU) does not have a PE ratio as the earnings reported over the last twelve months were negative (-8.4).


What is the market capitalization of ICU stock?

SEASTAR MEDICAL HOLDING CORP (ICU) has a market capitalization of 81.83M USD. This makes ICU a Micro Cap stock.